董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jesse Goodman | 男 | Independent Director | 73 | 45.00万美元 | 未持股 | 2026-08-07 |
| Georgia Keresty | 女 | Independent Director | 64 | 45.91万美元 | 未持股 | 2026-08-07 |
| Muna Bhanji | 女 | Independent Director | 62 | 98.62万美元 | 未持股 | 2026-08-07 |
| Frank Verwiel | 男 | Chairman of the Board | 62 | 49.58万美元 | 未持股 | 2026-08-07 |
| William Chase | 男 | Independent Director | 57 | 未披露 | 未持股 | 2026-08-07 |
| Brian Goff | -- | Independent Director | -- | 未披露 | 未持股 | 2026-08-07 |
| John M. Leonard | 男 | Director, President and Chief Executive Officer | 67 | 1009.66万美元 | 未持股 | 2026-08-07 |
| Fred Cohen | 男 | Independent Director | 69 | 45.25万美元 | 未持股 | 2026-08-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James Basta | 男 | Executive Vice President, General Counsel and Corporate Secretary | 59 | 362.52万美元 | 未持股 | 2026-08-07 |
| Eliana Clark | 女 | Executive Vice President and Chief Technology Officer | 68 | 未披露 | 未持股 | 2026-08-07 |
| Birgit Schultes | -- | Executive Vice President and Chief Scientific Officer | -- | 未披露 | 未持股 | 2026-08-07 |
| Michael P. Dube | -- | Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2026-08-07 |
| Edward J. Dulac, III | -- | Treasurer, Executive Vice President and Chief Financial Officer | -- | 未披露 | 未持股 | 2026-08-07 |
| John M. Leonard | 男 | Director, President and Chief Executive Officer | 67 | 1009.66万美元 | 未持股 | 2026-08-07 |
董事简历
中英对照 | 中文 | 英文- Jesse Goodman
-
Jesse Goodman， 2014年3月以来，他一直担任Georgetown大学医疗产品准入、安全和管理中心主任，以及医学教授和传染病主治医师。2016年至2025年，他担任跨国制药公司葛兰素史克（GlaxoSmithKline plc）的董事会成员，并担任董事会科学委员会主席，直到2023年初。自2018年以来，他担任Intellia Therapeutics， Inc.（上市生物技术公司）的董事会成员，现担任其科学和技术委员会主席。在合并协议之前，他曾担任APT董事会成员。他还曾担任美国药典公约公司（United States Pharmacopeia Convention, Inc.）董事会主席（2015年至2020年）和成员（2015年至2025年）。从2009年到2014年2月，他担任FDA的首席科学家。从2009年到2012年，他还担任FDA科学和公共卫生副专员。在此之前，他从2003年到2009年担任FDA生物制品评估和研究中心的主任，从1998年到2000年担任FDA专员的高级顾问。在他的政府服务之前，古德曼博士是明尼苏达大学的医学教授和传染病主任。古德曼博士曾任职于许多国家和国际卫生保健组织的咨询委员会和委员会，包括疾病预防控制中心、国家卫生研究所、世界卫生组织、流行病防范创新联盟和国家科学院、工程学院和医学院。他持有Harvard College的生物学学士学位、Minnesota大学的公共卫生硕士学位和the Albert Einstein College of Medicine的医学博士学位，并在Pennsylvania大学和California大学in Los Angeles接受了医学、传染病和肿瘤学的住院医师和奖学金培训，在那里他也是首席住院医师。他被选为国家医学院院士。
Jesse Goodman has served as a director of the Company since March 2024. Dr. Goodman has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectio diseases, at Georgetown University since March 2014. He served on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, from 2016 to 2025, and chaired that board's science committee until early 2023, and since 2018 has served on the board of directors of Intellia Therapeutics, Inc., a publicly traded biotechnology company, now chairing its science and technology committee. Prior to the Merger Agreement, Dr. Goodman served on the board of directors of APT. He also has served as a president (2015 to 2020) and member (2015 to 2025) of the board of trtees of the United States Pharmacopeia Convention, Inc. From 2009 until February 2014, Dr. Goodman served as the chief scientist of the FDA. Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of FDA's Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectio diseases at the University of Minnesota. Dr. Goodman has served on numero advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization, the Coalition on Epidemic Preparedness Innovations and the National Academies of Sciences, Engineering and Medicine. Dr. Goodman received a B.S. in biology from Harvard College, a master's in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectio diseases and oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also chief medical resident. He has been elected to the National Academy of Medicine. - Jesse Goodman， 2014年3月以来，他一直担任Georgetown大学医疗产品准入、安全和管理中心主任，以及医学教授和传染病主治医师。2016年至2025年，他担任跨国制药公司葛兰素史克（GlaxoSmithKline plc）的董事会成员，并担任董事会科学委员会主席，直到2023年初。自2018年以来，他担任Intellia Therapeutics， Inc.（上市生物技术公司）的董事会成员，现担任其科学和技术委员会主席。在合并协议之前，他曾担任APT董事会成员。他还曾担任美国药典公约公司（United States Pharmacopeia Convention, Inc.）董事会主席（2015年至2020年）和成员（2015年至2025年）。从2009年到2014年2月，他担任FDA的首席科学家。从2009年到2012年，他还担任FDA科学和公共卫生副专员。在此之前，他从2003年到2009年担任FDA生物制品评估和研究中心的主任，从1998年到2000年担任FDA专员的高级顾问。在他的政府服务之前，古德曼博士是明尼苏达大学的医学教授和传染病主任。古德曼博士曾任职于许多国家和国际卫生保健组织的咨询委员会和委员会，包括疾病预防控制中心、国家卫生研究所、世界卫生组织、流行病防范创新联盟和国家科学院、工程学院和医学院。他持有Harvard College的生物学学士学位、Minnesota大学的公共卫生硕士学位和the Albert Einstein College of Medicine的医学博士学位，并在Pennsylvania大学和California大学in Los Angeles接受了医学、传染病和肿瘤学的住院医师和奖学金培训，在那里他也是首席住院医师。他被选为国家医学院院士。
- Jesse Goodman has served as a director of the Company since March 2024. Dr. Goodman has been the director of the Center on Medical Product Access, Safety and Stewardship, and professor of medicine and attending physician in infectio diseases, at Georgetown University since March 2014. He served on the board of directors of GlaxoSmithKline plc, a multinational pharmaceutical company, from 2016 to 2025, and chaired that board's science committee until early 2023, and since 2018 has served on the board of directors of Intellia Therapeutics, Inc., a publicly traded biotechnology company, now chairing its science and technology committee. Prior to the Merger Agreement, Dr. Goodman served on the board of directors of APT. He also has served as a president (2015 to 2020) and member (2015 to 2025) of the board of trtees of the United States Pharmacopeia Convention, Inc. From 2009 until February 2014, Dr. Goodman served as the chief scientist of the FDA. Dr. Goodman also served as deputy commissioner for science and public health at the FDA from 2009 through 2012. Prior to that, Dr. Goodman was the director of FDA's Center for Biologics Evaluation and Research from 2003 to 2009 and a senior advisor to the FDA commissioner from 1998 through 2000. Prior to his government service, Dr. Goodman was professor of medicine and chief of infectio diseases at the University of Minnesota. Dr. Goodman has served on numero advisory boards and committees for national and international health care organizations, including the CDC, the National Institute of Health, the World Health Organization, the Coalition on Epidemic Preparedness Innovations and the National Academies of Sciences, Engineering and Medicine. Dr. Goodman received a B.S. in biology from Harvard College, a master's in public health from the University of Minnesota and an M.D. from the Albert Einstein College of Medicine, and did his residency and fellowship training in medicine, infectio diseases and oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles, where he was also chief medical resident. He has been elected to the National Academy of Medicine.
- Georgia Keresty
-
Georgia Keresty于2019年4月17日当选为董事会成员。自2017年以来，Keresty女士一直担任武田制药（Takeda Pharmaceuticals）的研发首席运营官，该公司是一家全球研究与开发驱动型创新生物制药公司。从2003年到2017年，以及从1997年到1999年，她是强生公司的高管。从1999年到2003年和从1983年到1997年，她分别在百时美施贵宝公司和诺华制药公司担任职务。她目前担任Depositing Agents，Inc.（员工持股计划全球工程服务公司）的独立董事，以及Clarkson University（位于纽约州波茨坦）的董事会成员，此前曾任职Janssen Alzheimer Immunotherapy公司的董事会。以及新泽西老龄基金会（NJ Foundation for Aging）的董事会。Keresty女士拥有Clarkson University和Ramapo College of New Jersey的化学工程和计算机科学学士学位，Pace University的信息系统硕士学位，Rutgers University的运营管理工商管理硕士学位，Rutgers University的运营管理博士学位；以及南加州大学（University of Southern California）全球健康领导力硕士学位。Keresty女士还是National Association of Corporate Directors NACD Directorship Certified™；
Georgia Keresty,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2021. Since February 2023, she has been the chief operating officer at a biotech startup that will operate as a CMC translational engine to deliver next-generation cell and gene therapy products. Dr. Keresty served as the chief operating officer for Takeda Research and Development ("Takeda R&D"), a division of Takeda Pharmaceuticals USA, Inc. ("Takeda") from December 2017 to December 2020. During Dr. Keresty's time at Takeda, she also served as Takeda R&D's global head of medical sciences and development operations. Prior to her time at Takeda, Dr. Keresty worked at Johnson & Johnson from July 2003 to September 2017, serving in multiple roles including as vice president and global head, pharmaceutical development and manufacturing science. Dr. Keresty has also worked at Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation. Dr. Keresty earned a B.S. in chemical engineering from Clarkson University and a B.S. in computer science from Ramapo College of New Jersey. Dr. Keresty also earned an M.S. in information systems from Pace University, an M.B.A. and Ph.D. in operations management from Rutgers Business School and an M.P.H. in Global Health Leadership from the University of Southern California. Dr. Keresty achieved her NACD Directorship Certification in September 2020, and serves on the board of directors of Solid Biosciences, Inc. She previously served on the board of directors of Aspen Technology, Inc., Commissioning Agents, Inc., and Janssen Alzheimer Immunotherapy as well as the boards of trustees for Clarkson University and the NJ Advocates for Aging Well. - Georgia Keresty于2019年4月17日当选为董事会成员。自2017年以来，Keresty女士一直担任武田制药（Takeda Pharmaceuticals）的研发首席运营官，该公司是一家全球研究与开发驱动型创新生物制药公司。从2003年到2017年，以及从1997年到1999年，她是强生公司的高管。从1999年到2003年和从1983年到1997年，她分别在百时美施贵宝公司和诺华制药公司担任职务。她目前担任Depositing Agents，Inc.（员工持股计划全球工程服务公司）的独立董事，以及Clarkson University（位于纽约州波茨坦）的董事会成员，此前曾任职Janssen Alzheimer Immunotherapy公司的董事会。以及新泽西老龄基金会（NJ Foundation for Aging）的董事会。Keresty女士拥有Clarkson University和Ramapo College of New Jersey的化学工程和计算机科学学士学位，Pace University的信息系统硕士学位，Rutgers University的运营管理工商管理硕士学位，Rutgers University的运营管理博士学位；以及南加州大学（University of Southern California）全球健康领导力硕士学位。Keresty女士还是National Association of Corporate Directors NACD Directorship Certified™；
- Georgia Keresty,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2021. Since February 2023, she has been the chief operating officer at a biotech startup that will operate as a CMC translational engine to deliver next-generation cell and gene therapy products. Dr. Keresty served as the chief operating officer for Takeda Research and Development ("Takeda R&D"), a division of Takeda Pharmaceuticals USA, Inc. ("Takeda") from December 2017 to December 2020. During Dr. Keresty's time at Takeda, she also served as Takeda R&D's global head of medical sciences and development operations. Prior to her time at Takeda, Dr. Keresty worked at Johnson & Johnson from July 2003 to September 2017, serving in multiple roles including as vice president and global head, pharmaceutical development and manufacturing science. Dr. Keresty has also worked at Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation. Dr. Keresty earned a B.S. in chemical engineering from Clarkson University and a B.S. in computer science from Ramapo College of New Jersey. Dr. Keresty also earned an M.S. in information systems from Pace University, an M.B.A. and Ph.D. in operations management from Rutgers Business School and an M.P.H. in Global Health Leadership from the University of Southern California. Dr. Keresty achieved her NACD Directorship Certification in September 2020, and serves on the board of directors of Solid Biosciences, Inc. She previously served on the board of directors of Aspen Technology, Inc., Commissioning Agents, Inc., and Janssen Alzheimer Immunotherapy as well as the boards of trustees for Clarkson University and the NJ Advocates for Aging Well.
- Muna Bhanji
-
Muna Bhanji，自2022年4月起担任Intellia Therapeutics，Inc.董事会成员。Bhanji女士是TIBA Global Access，LLC的创始人和负责人，该公司是一家自2021年1月起服务于生物制药行业的商业化和市场准入战略咨询公司。Bhanji女士此前曾在默克制药公司（“默沙东”）担任越来越多的职责，包括在美国和全球商业组织担任多个高级战略领导和运营职务，每年推动超过400 + 10亿美元的广泛药物和疫苗组合的增长。最近，Bhanji女士于2010年至2020年12月期间担任默沙东在世界各地的产品的全球市场准入和政策高级副总裁，负责为患者提供付款人报销和准入，并于2014年至2017年期间担任医院和专科特许经营高级副总裁。此外，Bhanji女士还担任默沙东全球肿瘤学和全球医院及专科商业特许经营高级副总裁。她目前在Cytokinetics，Inc.，Veracyte，Inc.和Ardelyx, Inc.的董事会任职。她还在Corus International的董事会任职。Corus International是一个由信仰组织组成的合奏，致力于世界上服务最欠缺的地区的扶贫和医疗保健的交叉领域。Bhanji女士获得了罗格斯药学院的药学学士学位和圣约瑟夫大学的工商管理硕士学位。
Muna Bhanji,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2022. Ms. Bhanji is the founder and principal of TIBA Global Access, LLC, a commercialization and market access strategy consultancy serving the biopharmaceutical industry since January 2021. Ms. Bhanji previously served in roles of increasing responsibility at Merck & Co., Inc. ("Merck"), including a number of senior strategic leadership and operating roles within the U.S. and global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, Ms. Bhanji served as the senior vice president, global market access & policy with responsibility for enabling payer reimbursement and access for patients, for Merck's products around the world from 2010 through December 2020 and as senior vice president, hospital & specialty franchises from 2014 until 2017. In addition, Ms. Bhanji served as senior vice president for global oncology and global hospital and specialty commercial franchises for Merck. She currently serves on the board of directors of Cytokinetics, Inc., Veracyte, Inc. and Ardelyx, Inc. She also serves on the board of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. Ms. Bhanji earned her B.Sc. in Pharmacy from Rutgers School of Pharmacy and an M.B.A. from St. Joseph's University. - Muna Bhanji，自2022年4月起担任Intellia Therapeutics，Inc.董事会成员。Bhanji女士是TIBA Global Access，LLC的创始人和负责人，该公司是一家自2021年1月起服务于生物制药行业的商业化和市场准入战略咨询公司。Bhanji女士此前曾在默克制药公司（“默沙东”）担任越来越多的职责，包括在美国和全球商业组织担任多个高级战略领导和运营职务，每年推动超过400 + 10亿美元的广泛药物和疫苗组合的增长。最近，Bhanji女士于2010年至2020年12月期间担任默沙东在世界各地的产品的全球市场准入和政策高级副总裁，负责为患者提供付款人报销和准入，并于2014年至2017年期间担任医院和专科特许经营高级副总裁。此外，Bhanji女士还担任默沙东全球肿瘤学和全球医院及专科商业特许经营高级副总裁。她目前在Cytokinetics，Inc.，Veracyte，Inc.和Ardelyx, Inc.的董事会任职。她还在Corus International的董事会任职。Corus International是一个由信仰组织组成的合奏，致力于世界上服务最欠缺的地区的扶贫和医疗保健的交叉领域。Bhanji女士获得了罗格斯药学院的药学学士学位和圣约瑟夫大学的工商管理硕士学位。
- Muna Bhanji,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2022. Ms. Bhanji is the founder and principal of TIBA Global Access, LLC, a commercialization and market access strategy consultancy serving the biopharmaceutical industry since January 2021. Ms. Bhanji previously served in roles of increasing responsibility at Merck & Co., Inc. ("Merck"), including a number of senior strategic leadership and operating roles within the U.S. and global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, Ms. Bhanji served as the senior vice president, global market access & policy with responsibility for enabling payer reimbursement and access for patients, for Merck's products around the world from 2010 through December 2020 and as senior vice president, hospital & specialty franchises from 2014 until 2017. In addition, Ms. Bhanji served as senior vice president for global oncology and global hospital and specialty commercial franchises for Merck. She currently serves on the board of directors of Cytokinetics, Inc., Veracyte, Inc. and Ardelyx, Inc. She also serves on the board of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. Ms. Bhanji earned her B.Sc. in Pharmacy from Rutgers School of Pharmacy and an M.B.A. from St. Joseph's University.
- Frank Verwiel
-
Frank Verwiel，自2017年7月加入为成员后，自2020年2月起担任Intellia Therapeutics，Inc.董事会主席。2005年7月至2008年2月，Verwiel博士担任公共专业制药公司Axcan Pharma，Inc.（“Axcan”）的总裁、首席执行官和董事会成员。Verwiel博士在2008年2月将Axcan私有化后继续履行这些职责，直到2014年2月，该公司已更名为Aptalis Pharma，Inc.（“Aptalis”），被森林实验室收购。在加入Aptalis之前，Verwiel博士曾在默沙东担任国际高级管理职务，包括在2001年6月至2005年5月期间担任高血压、全球人类健康营销副总裁。兼任默沙东全球高血压业务战略团队负责人。Verwiel博士还在1996年6月至2001年5月期间担任默沙东荷兰子公司的董事总经理。在任职于默沙东之前，他曾于1988年至1995年在制药公司赛维实验室担任国际领导职务。Verwiel博士目前在生物制药疫苗公司Bavarian Nordic A/S的董事会任职，该公司于2016年4月加入，自2019年8月起担任私人控股的生物制药公司Capsida BioTherapeutics Inc.的董事会成员。过去五年内，Verwiel博士还曾在以下上市生物技术和制药公司的董事会任职：生物制药公司ObsEva SA，2017年1月至2022年5月，Achillion Pharmaceuticals, Inc.（至2020年1月，被Alexion Inc.收购）和Avexis, Inc.（至2018年5月，被Novartis AG收购）。Verwiel博士还在2013年2月至2014年4月期间担任生物技术创新组织的董事会成员。Verwiel博士拥有荷兰鹿特丹Erasmus大学的医学博士学位和法国枫丹白露INSEAD的工商管理硕士学位。
Frank Verwiel,has served as the chairperson of Intellia Therapeutics, Inc. board of directors since February 2020 after joining as a member in July 2017. From July 2005 to February 2008, Dr. Verwiel served as president, chief executive officer and a member of the board of directors of Axcan Pharma, Inc. ("Axcan"), a public specialty pharmaceutical company. Dr. Verwiel continued with these responsibilities after taking Axcan private in February 2008 and through February 2014 when the company, which had changed its name to Aptalis Pharma, Inc. ("Aptalis"), was acquired by Forest Laboratories, Inc. Prior to joining Aptalis, Dr. Verwiel held international senior management positions with Merck, including as vice president, hypertension, worldwide human health marketing from June 2001 to May 2005. He concurrently served as a leader of Merck's worldwide hypertension business strategy team. Dr. Verwiel was also managing director of Merck's Dutch subsidiary from June 1996 to May 2001. Prior to his tenure at Merck, he had international leadership positions at Servier Laboratories, a pharmaceutical company, from 1988 until 1995. Dr. Verwiel currently serves on the boards of directors of Bavarian Nordic A/S, a biopharmaceutical vaccine company, which he joined in April 2016, and Capsida Biotherapeutics Inc., a privately held biopharmaceutical company, since August 2019. Within the last five years, Dr. Verwiel has also served on the boards of directors of the following public biotechnology and pharmaceutical companies: ObsEva SA, a biopharmaceutical company, from January 2017 to May 2022, Achillion Pharmaceuticals, Inc. (until January 2020, when it was acquired by Alexion Inc.) and Avexis, Inc. (until May 2018, when it was acquired by Novartis AG). Dr. Verwiel was also a member of the board of directors of the Biotechnology Innovation Organization from February 2013 to April 2014. Dr. Verwiel holds an M.D. from Erasmus University, Rotterdam in the Netherlands and an M.B.A. from INSEAD, Fontainebleau in France. - Frank Verwiel，自2017年7月加入为成员后，自2020年2月起担任Intellia Therapeutics，Inc.董事会主席。2005年7月至2008年2月，Verwiel博士担任公共专业制药公司Axcan Pharma，Inc.（“Axcan”）的总裁、首席执行官和董事会成员。Verwiel博士在2008年2月将Axcan私有化后继续履行这些职责，直到2014年2月，该公司已更名为Aptalis Pharma，Inc.（“Aptalis”），被森林实验室收购。在加入Aptalis之前，Verwiel博士曾在默沙东担任国际高级管理职务，包括在2001年6月至2005年5月期间担任高血压、全球人类健康营销副总裁。兼任默沙东全球高血压业务战略团队负责人。Verwiel博士还在1996年6月至2001年5月期间担任默沙东荷兰子公司的董事总经理。在任职于默沙东之前，他曾于1988年至1995年在制药公司赛维实验室担任国际领导职务。Verwiel博士目前在生物制药疫苗公司Bavarian Nordic A/S的董事会任职，该公司于2016年4月加入，自2019年8月起担任私人控股的生物制药公司Capsida BioTherapeutics Inc.的董事会成员。过去五年内，Verwiel博士还曾在以下上市生物技术和制药公司的董事会任职：生物制药公司ObsEva SA，2017年1月至2022年5月，Achillion Pharmaceuticals, Inc.（至2020年1月，被Alexion Inc.收购）和Avexis, Inc.（至2018年5月，被Novartis AG收购）。Verwiel博士还在2013年2月至2014年4月期间担任生物技术创新组织的董事会成员。Verwiel博士拥有荷兰鹿特丹Erasmus大学的医学博士学位和法国枫丹白露INSEAD的工商管理硕士学位。
- Frank Verwiel,has served as the chairperson of Intellia Therapeutics, Inc. board of directors since February 2020 after joining as a member in July 2017. From July 2005 to February 2008, Dr. Verwiel served as president, chief executive officer and a member of the board of directors of Axcan Pharma, Inc. ("Axcan"), a public specialty pharmaceutical company. Dr. Verwiel continued with these responsibilities after taking Axcan private in February 2008 and through February 2014 when the company, which had changed its name to Aptalis Pharma, Inc. ("Aptalis"), was acquired by Forest Laboratories, Inc. Prior to joining Aptalis, Dr. Verwiel held international senior management positions with Merck, including as vice president, hypertension, worldwide human health marketing from June 2001 to May 2005. He concurrently served as a leader of Merck's worldwide hypertension business strategy team. Dr. Verwiel was also managing director of Merck's Dutch subsidiary from June 1996 to May 2001. Prior to his tenure at Merck, he had international leadership positions at Servier Laboratories, a pharmaceutical company, from 1988 until 1995. Dr. Verwiel currently serves on the boards of directors of Bavarian Nordic A/S, a biopharmaceutical vaccine company, which he joined in April 2016, and Capsida Biotherapeutics Inc., a privately held biopharmaceutical company, since August 2019. Within the last five years, Dr. Verwiel has also served on the boards of directors of the following public biotechnology and pharmaceutical companies: ObsEva SA, a biopharmaceutical company, from January 2017 to May 2022, Achillion Pharmaceuticals, Inc. (until January 2020, when it was acquired by Alexion Inc.) and Avexis, Inc. (until May 2018, when it was acquired by Novartis AG). Dr. Verwiel was also a member of the board of directors of the Biotechnology Innovation Organization from February 2013 to April 2014. Dr. Verwiel holds an M.D. from Erasmus University, Rotterdam in the Netherlands and an M.B.A. from INSEAD, Fontainebleau in France.
- William Chase
-
William Chase，自2023年4月起担任Intellia Therapeutics，Inc.董事会成员。Chase先生于2018年10月至2019年7月在艾伯维公司（“艾伯维”）担任财务和行政执行副总裁，在此之前于2012年至2018年担任执行副总裁兼首席财务官。在这些职位上，他监督了所有金融、投资者和信息技术活动，并在艾伯维的许可和收购活动中发挥了关键的战略作用。在任职于艾伯维之前，他曾在雅培（“雅培”）担任多个财务和战略职位，包括负责许可与收购的公司副总裁、公司副总裁、财务主管，以及雅培国际公司的部门副总裁兼财务总监。他目前在Parexel International Corporation董事会任职。Chase先生拥有伊利诺伊大学金融学学士学位和芝加哥大学工商管理硕士学位。
William Chase,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2023. Mr. Chase served as Executive Vice President, Finance and Administration, for AbbVie Inc. ("AbbVie") from October 2018 to July 2019 and prior to that served as Executive Vice President and Chief Financial Officer from 2012 to 2018. In these roles he oversaw all financial, investor, and informational technology activities and played a critical strategic role in AbbVie's licensing and acquisition activities. Prior to his tenure at AbbVie, he served in a number of financial and strategic positions at Abbott Laboratories ("Abbott"), including Corporate Vice President, Licensing & Acquisitions, Corporate Vice President, Treasurer, and Divisional Vice President and Controller, Abbott International. He currently serves on the board of Parexel International Corporation. Mr. Chase holds a bachelor's degree in finance from the University of Illinois and an M.B.A. from the University of Chicago. - William Chase，自2023年4月起担任Intellia Therapeutics，Inc.董事会成员。Chase先生于2018年10月至2019年7月在艾伯维公司（“艾伯维”）担任财务和行政执行副总裁，在此之前于2012年至2018年担任执行副总裁兼首席财务官。在这些职位上，他监督了所有金融、投资者和信息技术活动，并在艾伯维的许可和收购活动中发挥了关键的战略作用。在任职于艾伯维之前，他曾在雅培（“雅培”）担任多个财务和战略职位，包括负责许可与收购的公司副总裁、公司副总裁、财务主管，以及雅培国际公司的部门副总裁兼财务总监。他目前在Parexel International Corporation董事会任职。Chase先生拥有伊利诺伊大学金融学学士学位和芝加哥大学工商管理硕士学位。
- William Chase,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2023. Mr. Chase served as Executive Vice President, Finance and Administration, for AbbVie Inc. ("AbbVie") from October 2018 to July 2019 and prior to that served as Executive Vice President and Chief Financial Officer from 2012 to 2018. In these roles he oversaw all financial, investor, and informational technology activities and played a critical strategic role in AbbVie's licensing and acquisition activities. Prior to his tenure at AbbVie, he served in a number of financial and strategic positions at Abbott Laboratories ("Abbott"), including Corporate Vice President, Licensing & Acquisitions, Corporate Vice President, Treasurer, and Divisional Vice President and Controller, Abbott International. He currently serves on the board of Parexel International Corporation. Mr. Chase holds a bachelor's degree in finance from the University of Illinois and an M.B.A. from the University of Chicago.
- Brian Goff
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- John M. Leonard
-
John M. Leonard，Intellia Therapeutics, Inc.，2014年至今，总裁兼首席执行官（2018年至今），研发执行副总裁（2017-2018年），首席医疗官（2014-2017年）。AbbVie Inc.首席科学官兼研发高级副总裁。雅培实验室全球药物研发高级副总裁等职。Intellia Therapeutics，Inc.，约翰霍普金斯大学医学博士，Wisconsin-Madison分校生物化学文学学士。
John M. Leonard,Intellia Therapeutics, Inc. (2014-present);President and Chief Executive Officer (2018-Present);Executive Vice President, Research and Development (2017-2018);Chief Medical Officer (2014-2017).Doctorate in Medicine, Johns Hopkins University;Bachelor of Arts in Biochemistry, University of Wisconsin-Madison. - John M. Leonard，Intellia Therapeutics, Inc.，2014年至今，总裁兼首席执行官（2018年至今），研发执行副总裁（2017-2018年），首席医疗官（2014-2017年）。AbbVie Inc.首席科学官兼研发高级副总裁。雅培实验室全球药物研发高级副总裁等职。Intellia Therapeutics，Inc.，约翰霍普金斯大学医学博士，Wisconsin-Madison分校生物化学文学学士。
- John M. Leonard,Intellia Therapeutics, Inc. (2014-present);President and Chief Executive Officer (2018-Present);Executive Vice President, Research and Development (2017-2018);Chief Medical Officer (2014-2017).Doctorate in Medicine, Johns Hopkins University;Bachelor of Arts in Biochemistry, University of Wisconsin-Madison.
- Fred Cohen
-
Fred Cohen，自2019年1月起担任Intellia治疗公司董事会成员。科恩博士于2021年创立了生命科学风险投资基金Monograph Capital Partners，并担任其董事长兼首席投资官。科恩博士还于2017年与他人共同创立了生物技术风险投资基金Vida Ventures，此后一直担任其高级董事总经理之一。2001-2016年，他是一家私募股权公司TPG的合伙人，并担任其于2001年创立的风险投资基金--生物技术集团—— TPG Biotech的共同负责人。科恩博士目前担任TPG的高级顾问。从1988年到2014年12月，科恩博士是加州大学旧金山分校（“加州大学旧金山分校”）细胞和分子药理学教授，他还担任过多项临床职责，包括担任研究科学家、住院患者内科医生、咨询内分泌学家以及内分泌和代谢科主任。他是加州大学旧金山分校基金会董事会成员。科恩博士目前在Progyny, Inc.、CareDx，Inc.和UroGenPharma Ltd.的董事会任职。在过去五年内，科恩博士还曾在以下上市生物技术和制药公司的董事会任职：Genomics Health，Inc.（至2019年11月）、Tandem Diabetes Care, Inc.（至2019年6月）、Biocryst医药，Inc.（至2019年1月）、TERM5，Inc.（至2018年5月）、Five Prime Therapeutics, Inc.“Five Prime Therapeutics，Inc.（至2018年5月）和Veracyte, Inc.”Veracyte，Inc.（至2021年6月）。科恩博士是私营Cell Design Labs的联合创始人和执行主席，该公司于2017年12月被吉利德科学公司（“吉利德”）收购。他拥有耶鲁大学分子生物物理学和生物化学学士学位、牛津大学分子生物物理学博士学位、斯坦福大学医学博士学位。科恩博士在加州大学旧金山分校完成了内科和内分泌学的博士后培训和研究生医学培训。他是美国医师学会和美国医学信息学学会会士，也是美国临床研究学会和美国医师协会的成员。科恩博士于2004年被选为美国国家医学研究院院士，并于2008年被选为美国艺术与科学院院士。科恩博士目前在多家私营生物技术和医疗保健公司的董事会任职。
Fred Cohen,has served as a member of Intellia Therapeutics, Inc. board of directors since January 2019. Dr. Cohen founded Monograph Capital Partners, a life sciences venture capital fund, in 2021, and serves as its chairman and chief investment officer. Dr. Cohen also co-founded Vida Ventures, a biotechnology venture capital fund, in 2017 and has served as one of its senior managing directors since then. From 2001 to 2016, he was a partner of TPG, a private equity company, and served as the cohead of its biotechnology group, TPG Biotech, a venture capital fund that he founded in 2001. Dr. Cohen currently serves as a senior advisor to TPG. From 1988 through December 2014, Dr. Cohen was a professor of cellular and molecular pharmacology at the University of California, San Francisco ("UCSF"), where he also held various clinical responsibilities, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and chief of the division of endocrinology and metabolism. He is a member of the board of trustees of the UCSF Foundation. Dr. Cohen currently serves on the boards of directors of Progyny, Inc., CareDx, Inc., and UroGen Pharma Ltd. Within the last five years, Dr. Cohen has also served on the boards of directors of the following public biotechnology and pharmaceutical companies: Genomics Health, Inc. (until November 2019), Tandem Diabetes Care, Inc. (until June 2019), BioCryst Pharmaceuticals, Inc. (until January 2019), Five Prime Therapeutics, Inc. (until May 2018) and Veracyte, Inc. (until June 2021). Dr. Cohen was a co-founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. ("Gilead") in December 2017. He holds a B.S. in molecular biophysics and biochemistry from Yale University, a D.Phil. in molecular biophysics from Oxford University, and an M.D. from Stanford University. Dr. Cohen completed his postdoctoral training and postgraduate medical training in internal medicine and endocrinology at UCSF. He is a fellow of the American College of Physicians and the American College of Medical Informatics, and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen as elected to the National Academy of Medicine in 2004 and the American Academy of Arts and Sciences in 2008. Dr. Cohen currently serves on the board of directors of various private biotechnology and healthcare companies. - Fred Cohen，自2019年1月起担任Intellia治疗公司董事会成员。科恩博士于2021年创立了生命科学风险投资基金Monograph Capital Partners，并担任其董事长兼首席投资官。科恩博士还于2017年与他人共同创立了生物技术风险投资基金Vida Ventures，此后一直担任其高级董事总经理之一。2001-2016年，他是一家私募股权公司TPG的合伙人，并担任其于2001年创立的风险投资基金--生物技术集团—— TPG Biotech的共同负责人。科恩博士目前担任TPG的高级顾问。从1988年到2014年12月，科恩博士是加州大学旧金山分校（“加州大学旧金山分校”）细胞和分子药理学教授，他还担任过多项临床职责，包括担任研究科学家、住院患者内科医生、咨询内分泌学家以及内分泌和代谢科主任。他是加州大学旧金山分校基金会董事会成员。科恩博士目前在Progyny, Inc.、CareDx，Inc.和UroGenPharma Ltd.的董事会任职。在过去五年内，科恩博士还曾在以下上市生物技术和制药公司的董事会任职：Genomics Health，Inc.（至2019年11月）、Tandem Diabetes Care, Inc.（至2019年6月）、Biocryst医药，Inc.（至2019年1月）、TERM5，Inc.（至2018年5月）、Five Prime Therapeutics, Inc.“Five Prime Therapeutics，Inc.（至2018年5月）和Veracyte, Inc.”Veracyte，Inc.（至2021年6月）。科恩博士是私营Cell Design Labs的联合创始人和执行主席，该公司于2017年12月被吉利德科学公司（“吉利德”）收购。他拥有耶鲁大学分子生物物理学和生物化学学士学位、牛津大学分子生物物理学博士学位、斯坦福大学医学博士学位。科恩博士在加州大学旧金山分校完成了内科和内分泌学的博士后培训和研究生医学培训。他是美国医师学会和美国医学信息学学会会士，也是美国临床研究学会和美国医师协会的成员。科恩博士于2004年被选为美国国家医学研究院院士，并于2008年被选为美国艺术与科学院院士。科恩博士目前在多家私营生物技术和医疗保健公司的董事会任职。
- Fred Cohen,has served as a member of Intellia Therapeutics, Inc. board of directors since January 2019. Dr. Cohen founded Monograph Capital Partners, a life sciences venture capital fund, in 2021, and serves as its chairman and chief investment officer. Dr. Cohen also co-founded Vida Ventures, a biotechnology venture capital fund, in 2017 and has served as one of its senior managing directors since then. From 2001 to 2016, he was a partner of TPG, a private equity company, and served as the cohead of its biotechnology group, TPG Biotech, a venture capital fund that he founded in 2001. Dr. Cohen currently serves as a senior advisor to TPG. From 1988 through December 2014, Dr. Cohen was a professor of cellular and molecular pharmacology at the University of California, San Francisco ("UCSF"), where he also held various clinical responsibilities, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and chief of the division of endocrinology and metabolism. He is a member of the board of trustees of the UCSF Foundation. Dr. Cohen currently serves on the boards of directors of Progyny, Inc., CareDx, Inc., and UroGen Pharma Ltd. Within the last five years, Dr. Cohen has also served on the boards of directors of the following public biotechnology and pharmaceutical companies: Genomics Health, Inc. (until November 2019), Tandem Diabetes Care, Inc. (until June 2019), BioCryst Pharmaceuticals, Inc. (until January 2019), Five Prime Therapeutics, Inc. (until May 2018) and Veracyte, Inc. (until June 2021). Dr. Cohen was a co-founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. ("Gilead") in December 2017. He holds a B.S. in molecular biophysics and biochemistry from Yale University, a D.Phil. in molecular biophysics from Oxford University, and an M.D. from Stanford University. Dr. Cohen completed his postdoctoral training and postgraduate medical training in internal medicine and endocrinology at UCSF. He is a fellow of the American College of Physicians and the American College of Medical Informatics, and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen as elected to the National Academy of Medicine in 2004 and the American Academy of Arts and Sciences in 2008. Dr. Cohen currently serves on the board of directors of various private biotechnology and healthcare companies.
高管简历
中英对照 | 中文 | 英文- James Basta
James Basta，自2021年6月起担任Intellia Therapeutics，Inc.执行副总裁、总法律顾问和公司秘书。在加入Intellia之前，Basta先生于2019年11月至2021年6月在Kura Oncology, Inc.（“Kura”）担任首席法务官和秘书。在加入Kura之前，他在渤健工作了13年，从2006年到2019年，最近担任高级副总裁兼首席公司法律顾问，管理渤健证券备案、董事会、业务发展、财税、公司事务、就业和信息技术的法律代表。在加入渤健之前，他是Baker & McKenzie公司和证券业务组的合伙人。巴斯塔先生在西北大学化学生命过程研究所的执行顾问委员会任职。他在西北大学普利兹克法学院获得法学博士学位，并在西北大学获得经济学学士学位。
James Basta,has served as Intellia Therapeutics, Inc. executive vice president, general counsel and corporate secretary since June 2021. Prior to joining Intellia, Mr. Basta served as chief legal officer and secretary at Kura Oncology, Inc. ("Kura") from November 2019 to June 2021. Prior to Kura, he spent 13 years at Biogen, from 2006 through 2019, where he most recently served as senior vice president and chief corporation counsel, managing the legal representation for Biogen's securities filings, board of directors, business development, finance and tax, corporate affairs, employment and information technology. Prior to joining Biogen, he was a partner in the Corporate and Securities Practice Group at Baker & McKenzie. Mr. Basta serves on the executive advisory board of the Chemistry Life Processes Institute at Northwestern University. He earned his J.D. from Northwestern University Pritzker School of Law and his B.A. in economics from Northwestern University.- James Basta，自2021年6月起担任Intellia Therapeutics，Inc.执行副总裁、总法律顾问和公司秘书。在加入Intellia之前，Basta先生于2019年11月至2021年6月在Kura Oncology, Inc.（“Kura”）担任首席法务官和秘书。在加入Kura之前，他在渤健工作了13年，从2006年到2019年，最近担任高级副总裁兼首席公司法律顾问，管理渤健证券备案、董事会、业务发展、财税、公司事务、就业和信息技术的法律代表。在加入渤健之前，他是Baker & McKenzie公司和证券业务组的合伙人。巴斯塔先生在西北大学化学生命过程研究所的执行顾问委员会任职。他在西北大学普利兹克法学院获得法学博士学位，并在西北大学获得经济学学士学位。
- James Basta,has served as Intellia Therapeutics, Inc. executive vice president, general counsel and corporate secretary since June 2021. Prior to joining Intellia, Mr. Basta served as chief legal officer and secretary at Kura Oncology, Inc. ("Kura") from November 2019 to June 2021. Prior to Kura, he spent 13 years at Biogen, from 2006 through 2019, where he most recently served as senior vice president and chief corporation counsel, managing the legal representation for Biogen's securities filings, board of directors, business development, finance and tax, corporate affairs, employment and information technology. Prior to joining Biogen, he was a partner in the Corporate and Securities Practice Group at Baker & McKenzie. Mr. Basta serves on the executive advisory board of the Chemistry Life Processes Institute at Northwestern University. He earned his J.D. from Northwestern University Pritzker School of Law and his B.A. in economics from Northwestern University.
- Eliana Clark
Eliana Clark，自2022年2月起担任Intellia Therapeutics，Inc.执行副总裁、首席技术官。在担任现职之前，Clark博士自2020年1月起担任Intellia Therapeutics，Inc.技术运营高级副总裁。在加入Intellia之前，她在渤健担任了七年的领导职务，包括从2016年12月到2019年6月的国际制造业务副总裁，以及从2019年7月到2019年12月的产品开发和产品组合管理副总裁，在那里她领导的团队负责CMC产品战略、供应和整个产品组合的生命周期管理。在加入渤健之前，Clark博士曾在赛诺菲/健赞公司工作多年，在那里她在制剂开发、技术服务和CMC监管方面担任领导职务。在从事工业工作之前，她曾在塔夫茨大学化学和生物工程系担任教授近15年。克拉克博士拥有阿根廷圣达菲国立滨海大学化学工程学士和博士学位，毕业于麻省理工学院斯隆管理学院的大波士顿执行项目。
Eliana Clark,has served as Intellia Therapeutics, Inc. executive vice president, chief technology officer since February 2022. Prior to her current role, Dr. Clark served as Intellia Therapeutics, Inc. senior vice president of technical operations since January 2020. Prior to Intellia, she spent seven years in leadership roles at Biogen, including vice president of international manufacturing operations from December 2016 through June 2019 and vice president of product development and portfolio management, where she led the team responsible for CMC product strategy, supply and lifecycle management for their entire product portfolio, from July 2019 through December 2019. Before Biogen, Dr. Clark spent many years at Sanofi/Genzyme, where she held leadership roles in formulation development, technical services and CMC regulatory. Prior to working in industry, she was a professor at Tufts University in the Chemical and Biological Engineering Department for nearly 15 years. Dr. Clark holds a B.E. and Ph.D. in chemical engineering from the Universidad Nacional de Litoral in Santa Fe, Argentina, and graduated from the Greater Boston Executive Program at MIT Sloan School of Management.- Eliana Clark，自2022年2月起担任Intellia Therapeutics，Inc.执行副总裁、首席技术官。在担任现职之前，Clark博士自2020年1月起担任Intellia Therapeutics，Inc.技术运营高级副总裁。在加入Intellia之前，她在渤健担任了七年的领导职务，包括从2016年12月到2019年6月的国际制造业务副总裁，以及从2019年7月到2019年12月的产品开发和产品组合管理副总裁，在那里她领导的团队负责CMC产品战略、供应和整个产品组合的生命周期管理。在加入渤健之前，Clark博士曾在赛诺菲/健赞公司工作多年，在那里她在制剂开发、技术服务和CMC监管方面担任领导职务。在从事工业工作之前，她曾在塔夫茨大学化学和生物工程系担任教授近15年。克拉克博士拥有阿根廷圣达菲国立滨海大学化学工程学士和博士学位，毕业于麻省理工学院斯隆管理学院的大波士顿执行项目。
- Eliana Clark,has served as Intellia Therapeutics, Inc. executive vice president, chief technology officer since February 2022. Prior to her current role, Dr. Clark served as Intellia Therapeutics, Inc. senior vice president of technical operations since January 2020. Prior to Intellia, she spent seven years in leadership roles at Biogen, including vice president of international manufacturing operations from December 2016 through June 2019 and vice president of product development and portfolio management, where she led the team responsible for CMC product strategy, supply and lifecycle management for their entire product portfolio, from July 2019 through December 2019. Before Biogen, Dr. Clark spent many years at Sanofi/Genzyme, where she held leadership roles in formulation development, technical services and CMC regulatory. Prior to working in industry, she was a professor at Tufts University in the Chemical and Biological Engineering Department for nearly 15 years. Dr. Clark holds a B.E. and Ph.D. in chemical engineering from the Universidad Nacional de Litoral in Santa Fe, Argentina, and graduated from the Greater Boston Executive Program at MIT Sloan School of Management.
- Birgit Schultes
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Michael P. Dube
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Edward J. Dulac, III
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- John M. Leonard
John M. Leonard，Intellia Therapeutics, Inc.，2014年至今，总裁兼首席执行官（2018年至今），研发执行副总裁（2017-2018年），首席医疗官（2014-2017年）。AbbVie Inc.首席科学官兼研发高级副总裁。雅培实验室全球药物研发高级副总裁等职。Intellia Therapeutics，Inc.，约翰霍普金斯大学医学博士，Wisconsin-Madison分校生物化学文学学士。
John M. Leonard,Intellia Therapeutics, Inc. (2014-present);President and Chief Executive Officer (2018-Present);Executive Vice President, Research and Development (2017-2018);Chief Medical Officer (2014-2017).Doctorate in Medicine, Johns Hopkins University;Bachelor of Arts in Biochemistry, University of Wisconsin-Madison.- John M. Leonard，Intellia Therapeutics, Inc.，2014年至今，总裁兼首席执行官（2018年至今），研发执行副总裁（2017-2018年），首席医疗官（2014-2017年）。AbbVie Inc.首席科学官兼研发高级副总裁。雅培实验室全球药物研发高级副总裁等职。Intellia Therapeutics，Inc.，约翰霍普金斯大学医学博士，Wisconsin-Madison分校生物化学文学学士。
- John M. Leonard,Intellia Therapeutics, Inc. (2014-present);President and Chief Executive Officer (2018-Present);Executive Vice President, Research and Development (2017-2018);Chief Medical Officer (2014-2017).Doctorate in Medicine, Johns Hopkins University;Bachelor of Arts in Biochemistry, University of Wisconsin-Madison.